10x GenomicsTXG -0.86%62 Net Debt Paydown Yield % is -0.01% as of Jul. 11, 2026. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.94 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 624 Healthcare Providers & Services companies, 10x Genomics ranks better than 54.01% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, 10x Genomics's Net Debt Paydown Yield % was -0.01%.
10x Genomics (NAS:TXG) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
10x Genomics Net Debt Paydown Yield % Related Terms
10x Genomics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXG vs DOCS, WAY, PRVA: Net Debt Paydown Yield % Comparison
For the Health Information Services subindustry, 10x Genomics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Net Debt Paydown Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -0.01% mean?
10x Genomics (TXG) has a Net Debt Paydown Yield % of -0.01% as of Jul. 11, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #287 out of 624 companies in the Healthcare Providers & Services industry, placing it in the top 46%.
Is 10x Genomics' Net Debt Paydown Yield % too high?
10x Genomics' current Net Debt Paydown Yield % is -0.01%. Based on the distribution chart, 10x Genomics ranks #287 out of 624 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Net Debt Paydown Yield % compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #287 out of 624 companies for Net Debt Paydown Yield %. This puts 10x Genomics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Healthcare Providers & Services company?
A good Net Debt Paydown Yield % depends on the Healthcare Providers & Services industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on 10x Genomics and its competitors. 10x Genomics's current Net Debt Paydown Yield % is -0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.94, compared to a current price of $42.75 — trading 125.7% above its estimated fair value. The current Net Debt Paydown Yield % is -0.01%. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For 10x Genomics (TXG), the current Net Debt Paydown Yield % is -0.01% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $42.75 is trading 125.7% above its estimated GF Value™ of $18.94.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Net Debt Paydown Yield %: -0.01%
GF Value™: $18.94 vs. price of $42.75 (125.7% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
